Sonoma Pharmaceuticals In... (SNOA)
2.63
-0.01 (-0.38%)
At close: Jan 14, 2025, 3:59 PM
2.64
0.21%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.49 |
| Market Cap | 3.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.99 |
| PE Ratio (ttm) | -2.66 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.77 |
| Volume | 18,378 |
| Avg. Volume (20D) | 315,695 |
| Open | 2.63 |
| Previous Close | 2.64 |
| Day's Range | 2.59 - 2.69 |
| 52-Week Range | 2.44 - 9.40 |
| Beta | undefined |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; ...
Sector Healthcare
IPO Date Jan 25, 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol SNOA
Website https://www.sonomapharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SNOA stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Sonoma Pharmaceuticals Inc. is scheduled to release its earnings on Feb 6, 2025,
during market hours.
Analysts project revenue of $4.39M, reflecting a 39.90% YoY growth and earnings per share of -0.8, making a -50.00% decrease YoY.
Analysts project revenue of $4.39M, reflecting a 39.90% YoY growth and earnings per share of -0.8, making a -50.00% decrease YoY.
2 months ago ·
Source
+10.71%
Sonoma Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
4 months ago ·
Source
+20.29%
Sonoma Pharmaceuticals shares are trading higher after the company was granted FDA 510(k) clearance for its microdacyn wound care solution.
